UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 116

Sortiert nach

NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient

Haematologica (Roma), 2018-09, Vol.103 (9), p.e424

2018

Link zum Volltext

Verfügbarkeit prüfen

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types

BMJ open, 2017-11, Vol.7 (11), p.e017075-e017075

2017

Link zum Volltext

Verfügbarkeit prüfen

Developing strategies in the immunotherapy of leukemias

Cancer control, 2013-01, Vol.20 (1), p.49-59

2013

Link zum Volltext

Verfügbarkeit prüfen

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma

Blood advances, 2022-12, Vol.6 (24), p.6109-6119

2022

Link zum Volltext

Verfügbarkeit prüfen

Connecting the Dots: A Case of Myeloid Sarcoma

The American journal of medicine, 2018-09, Vol.131 (9), p.e357-e359

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3101: Functional analysis of HDAC11 in plasma cell development and multiple myeloma survival

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3101-3101

2019

Link zum Volltext

Verfügbarkeit prüfen

Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment

Journal of immunotherapy (1997), 2014-04, Vol.37 (3), p.187

2014

Link zum Volltext

Verfügbarkeit prüfen

A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.4399-4399

2021

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study

Blood, 2022-11, Vol.140 (Supplement 1), p.7313-7314

2022

Link zum Volltext

Verfügbarkeit prüfen

Immune Profiles of Myeloma Tumor Microenvironment May Predict Sensitivity or Resistance to Elotuzumab

Blood, 2021-11, Vol.138 (Supplement 1), p.2682-2682

2021

Link zum Volltext

Verfügbarkeit prüfen

The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma

Therapeutic Advances in Hematology, 2017-07, Vol.8 (7), p.209-220

2017

Link zum Volltext

Verfügbarkeit prüfen

Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient's Monitoring after CAR T-Cell Therapy

Blood, 2022-11, Vol.140 (Supplement 1), p.7538-7539

2022

Link zum Volltext

Verfügbarkeit prüfen

Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience

Blood, 2022-11, Vol.140 (Supplement 1), p.4856-4858

2022

Link zum Volltext

Verfügbarkeit prüfen

Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.5174-5176

2022

Link zum Volltext

Verfügbarkeit prüfen

Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma

Clinical cancer research, 2023-11, Vol.29 (22), p.4575

2023

Link zum Volltext

Verfügbarkeit prüfen

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

Cancer research (Chicago, Ill.), 2004-08, Vol.64 (16), p.5839-5849

2004

Link zum Volltext

Verfügbarkeit prüfen

WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides

American journal of hematology, 2015-07, Vol.90 (7), p.602-607

2015

Link zum Volltext

Verfügbarkeit prüfen

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Blood, 2021-11, Vol.138 (Supplement 1), p.2817-2817

2021

Link zum Volltext

Verfügbarkeit prüfen

Association of venetoclax-based therapy with increased survival in multiple myeloma (MM) harboring t(11;14): A single-center experience

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e20055-e20055

2023

Link zum Volltext

Verfügbarkeit prüfen

High-Dimensional Flow Cytometry Analysis of Regulatory Receptors on Human T Cells, NK Cells, and NKT Cells

Methods in molecular biology (Clifton, N.J.), 2021, Vol.2194, p.255

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical presentation and outcome of patients with AL amyloidosis requiring salvage therapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e20043-e20043

2021

Link zum Volltext

Verfügbarkeit prüfen

High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.10402-10404

2022

Link zum Volltext

Verfügbarkeit prüfen

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Blood, 2022-11, Vol.140 (Supplement 1), p.10140-10141

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(109)

Publikationsform

Sprache

Englisch
(116)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(34)
Humans
(18)
Animals
(17)
Mice
(17)
Hematology
(11)
Immunology
(11)
Male
(11)
Biological And Medical Sciences
(9)
Female
(9)
Mice, Inbred Balb C
(9)
Oncology
(9)
Medical Sciences
(8)
Mice, Inbred C57bl
(7)
Mice, Inbred Nod
(7)
Multiple Myeloma
(6)
Rheumatology
(6)
Aged
(4)
Cd4-Positive T-Lymphocytes - Immunology
(4)
Disease Models, Animal
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types

Developing strategies in the immunotherapy of leukemias

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma

Connecting the Dots: A Case of Myeloid Sarcoma

Abstract 3101: Functional analysis of HDAC11 in plasma cell development and multiple myeloma survival

Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment

A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study

Immune Profiles of Myeloma Tumor Microenvironment May Predict Sensitivity or Resistance to Elotuzumab

The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma

Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient's Monitoring after CAR T-Cell Therapy

Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience

Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Association of venetoclax-based therapy with increased survival in multiple myeloma (MM) harboring t(11;14): A single-center experience

High-Dimensional Flow Cytometry Analysis of Regulatory Receptors on Human T Cells, NK Cells, and NKT Cells

Clinical presentation and outcome of patients with AL amyloidosis requiring salvage therapy

High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Suchergebnisse filtern